Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma

2015-12-01

Leukemia , Volume 29 - Issue 12 p. 2429- 2431

Additional Metadata
Persistent URL	doi.org/10.1038/leu.2015.274, hdl.handle.net/1765/89063
Journal	Leukemia
Rights	no subscription
Organisation	Department of Hematology
Citation APA APA Style APA-ALL Style AAA Style Cell Style Chicago Style Harvard Style IEEE Style MLA Style Nature Style Vancouver Style American-Institute-of-Physics Style Council-of-Science-Editors Style BibTex Format Endnote Format RIS Format CSL Format DOIs only Format	Cavo, M., Pantani, L., Pezzi, A., Petrucci, M., Patriarca, F., Di Raimondo, F., Marzocchi, G., Galli, M., Montefusco, V., Zamagni, E., Gamberi, B., Tacchetti, P., Brioli, A., Palumbo, A.& Sonneveld, P. (2015). Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma. Leukemia, 29(12), 2429–2431.https://doi.org/10.1038/leu.2015.274

Publication